Abstract
Objective: The aim of this study was to determine the effect of treatment on endotelin‐1 concentration that is considered to have role in etiopathogenesis of eclampsia and preeclampsia. Methods: Nine patients with eclampsia and 12 patients with preeclampsia were included to the study. Endothelin‐1 levels were measured before and after magnesium sulfate treatment. After the magnesium sulfate administration, if the blood pressure was still elevated, nifedipine was given. Results: Endothelin‐1 levels of preeclamptic patients before and after magnesium sulfate treatment were 16.9 ± 2.3 fmol/ml and 14.6 ± 1.9 fmol/ml respectively (p < 0.05). The same measurements of eclamptic patients were 18.1 ± 3.2 and 14.7 ± 3.4 respectively (p < 0.05). The mean blood pressures of preeclamptic patients before and after magnesium sulfate were 125.8 ± 7.3 mm‐Hg, 118.2 ± 8.7 mm‐Hg respectively, and the same measurements of eclamptic patients were 136.0 ± 12.4 mm‐Hg and 123.1 ± 10.6 mm‐Hg respectively (p < 0.05, p < 0.05). Conclusion: Treatment had been found to have negative effects on endothelin‐1 levels that is considered to play an important role on etiopathogenesis of eclampsia and preeclampsia.